COMMUNIQUÉS West-GlobeNewswire

AMN Healthcare Named One of America’s Greatest Workplaces for Diversity by Newsweek
05/02/2024
DALLAS, Feb. 05, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, has been recognized as one [...]
Inteleos and Credivera Partner to Revolutionize Global Healthcare Credentialing
05/02/2024
Digital Identities and Verifiable Credentials To Increase Customer Data Security ROCKVILLE, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- In a groundbreaking partnership, Inteleos a non-profit global healthcare certification [...]
Discoverer of the Klotho Gene and Pioneer in Longevity and Disease Prevention Dr. Makoto Kuro-o Joins Scientific Advisory Board of ADvantage Therapeutics
05/02/2024
Dr. Kuro-o to speak at Second Annual Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton, Florida BOCA RATON, Fla. and VIENNA, Austria, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, a [...]
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
05/02/2024
Six posters and oral presentations to be presented, including efficacy data for neffy from two distinct clinical studies in oral food challenge induced anaphylaxis and chronic urticaria patients 100% response rate with [...]
Curia Receives 2024 CDMO Leadership Award
05/02/2024
Curia recognized for its Service in the CDMO industry ALBANY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a [...]
Canada-based Cinim included as part of international digital series, In Pursuit of Wellness
05/02/2024
Launched on January 18, 2024 this limited series looks at modern wellness practices that span generations and cultures around the world CALGARY, Alberta, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Today, Cinim (Canadian [...]
ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)
05/02/2024
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in a Phase I/II clinical trial for primary CNS tumors driven by MYC or MYCN [...]
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
05/02/2024
Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET WALTHAM, Mass. and BOULDER, Colo., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company [...]
Spectral AI Announces Publication of Letter to Shareholders
05/02/2024
DALLAS, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
05/02/2024
NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of [...]
Curia reçoit le CDMO Leadership Award 2024
05/02/2024
Curia est ainsi reconnue pour son service dans le secteur des organisations de développement et de fabrication sous contrat ALBANY, New York, 05 févr. 2024 (GLOBE NEWSWIRE) -- Curia, une organisation de développement et [...]
Intelligent Bio Solutions Inc. Announces Exercise of Previously Issued Warrants for $1.77 Million in Gross Proceeds
05/02/2024
NEW YORK, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain
05/02/2024
RIYADH, Saudi Arabia, Feb. 05, 2024 (GLOBE NEWSWIRE) -- In a major scientific breakthrough, a research team from King Faisal Specialist Hospital and Research Centre (KFSH&RC), in collaboration with King Abdullah [...]
MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product
05/02/2024
The Dallas Based, Direct-to-Consumer Telemedicine Company to Offer 2 Months of Free ‘PRIME’ by MangoRx, Powered by Kyzatrex ®️ (a $498 value) for First 1,000 Subscribers Dallas, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- [...]
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
05/02/2024
ROCKVILLE, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
05/02/2024
CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President [...]
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
05/02/2024
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the [...]
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
05/02/2024
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the [...]
Chiesi Global Rare Diseases Announces Health Canada Approval of MYALEPTA™ (metreleptin for injection) for the Treatment of Patients with Lipodystrophy
05/02/2024
Canadian patients living with this ultra-rare condition welcome this new treatment option BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver [...]

Pages